scholarly journals P05.54 Meningioma surgery in the elderly, a retrospective population based registry study

2018 ◽  
Vol 20 (suppl_3) ◽  
pp. iii315-iii315
Author(s):  
D Löfgren ◽  
M Olivecrona
Keyword(s):  
The Elderly ◽  
Population Based ◽  
Registry Study ◽  
Surgery In The Elderly ◽  
Meningioma Surgery ◽  
Population Based Registry

scholarly journals Trend in the use of topical ocular anti-infectives in a region of Spain between 2015 and 2019: a population-based registry study

2020 ◽  
Vol 33 (6) ◽  
pp. 453-458
Author(s):  
Eduardo Gutiérrez-Abejón ◽  
Francisco Herrera-Gómez ◽  
Ignacio J. Ayestarán-Martínez ◽  
Francisco Javier Álvarez ◽  
Keyword(s):  
Population Distribution ◽  
The Elderly ◽  
Population Based ◽  
European Population ◽  
Registry Study ◽  
Total Consumption ◽  
Age And Gender ◽  
Ocular Drugs ◽  
And Gender ◽  
Population Based Registry

Objectives. This study presents the use and trends of use of topical ocular anti-infectives into a European population in the current decade (2015 to 2019) with an analysis of concomitant use with other ocular drugs, considering distribution by age and gender. Patients and Methods. A population-based registry study was carried out to assess the ocular anti-infectives use from 2015 to 2019. All dispensations of these medicines at pharmacies in the largest region of Spain, Castile and León, was accessed. The number of packages dispensed, the percentage of the population under treatment, diagnosis, and the concomitant use with other ocular medicines was observed. For all analyses, the population distribution by age and gender was considered. Results. An average of 198,000 packages of topical ocular anti-infectives were dispensed annually to 5.38% of the population, and more commonly for women than for men (5.83% vs. 4.91%). Children and the elderly used more these medicines. Tobramycin, alone or in combination, accounted for more than 68% of the total consumption (135,000 packages per year), and was the most widely used anti-infective in almost all identified diagnoses. Conjunctivitis (50.12%), and stye (11.51%) were the most frequent diagnoses. The consumption of ocular anti-infectives increased by 8.23% from 2015 to 2019, and more among men than in women. Conclusions. Our findings show that the most used topical ocular anti-infective was tobramycin, in accordance with the clinical practice guidelines recommendations. However, ocular infections are sometimes treated empirically, especially conjunctivitis.

Neonatal and maternal outcome after blastocyst transfer: a population-based registry study

2016 ◽  
Vol 214 (3) ◽  
pp. 378.e1-378.e10 ◽  
Author(s):  
Erica Ginström Ernstad ◽  
Christina Bergh ◽  
Ali Khatibi ◽  
Karin B.M. Källén ◽  
Göran Westlander ◽  
...  
Keyword(s):  
Population Based ◽  
Maternal Outcome ◽  
Blastocyst Transfer ◽  
Registry Study ◽  
Population Based Registry

scholarly journals The burden and costs of prevention and management of genital disease caused by HPV in women: A population-based registry study in Finland

2013 ◽  
Vol 133 (6) ◽  
pp. 1459-1469 ◽  
Author(s):  
Heini Salo ◽  
Tuija Leino ◽  
Terhi Kilpi ◽  
Kari Auranen ◽  
Petri Tiihonen ◽  
...  
Keyword(s):  
Population Based ◽  
Registry Study ◽  
Population Based Registry ◽  
Genital Disease

Riluzole and other prognostic factors in ALS: a population-based registry study in Italy

2018 ◽  
Vol 265 (4) ◽  
pp. 817-827 ◽  
Author(s):  
Jessica Mandrioli ◽  
◽  
Sara Angela Malerba ◽  
Ettore Beghi ◽  
Nicola Fini ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Population Based ◽  
Registry Study ◽  
Population Based Registry

scholarly journals Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Julio García-Suárez ◽  
◽  
Javier de la Cruz ◽  
Ángel Cedillo ◽  
Pilar Llamas ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Cancer Therapy ◽  
Hematologic Malignancy ◽  
Large Population ◽  
Hematologic Malignancies ◽  
Population Based ◽  
Clinical Severity ◽  
Primary Study ◽  
Registry Study ◽  
Population Based Registry

Abstract Background Patients with cancer have been shown to have a higher risk of clinical severity and mortality compared to non-cancer patients with COVID-19. Patients with hematologic malignancies typically are known to have higher levels of immunosuppression and may develop more severe respiratory viral infections than patients with solid tumors. Data on COVID-19 in patients with hematologic malignancies are limited. Here we characterize disease severity and mortality and evaluate potential prognostic factors for mortality. Methods In this population-based registry study, we collected de-identified data on clinical characteristics, treatment and outcomes in adult patients with hematologic malignancies and confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection within the Madrid region of Spain. Our case series included all patients admitted to 22 regional health service hospitals and 5 private healthcare centers between February 28 and May 25, 2020. The primary study outcome was all-cause mortality. We assessed the association between mortality and potential prognostic factors using Cox regression analyses adjusted for age, sex, comorbidities, hematologic malignancy and recent active cancer therapy. Results Of 833 patients reported, 697 were included in the analyses. Median age was 72 years (IQR 60–79), 413 (60%) patients were male and 479 (69%) and 218 (31%) had lymphoid and myeloid malignancies, respectively. Clinical severity of COVID-19 was severe/critical in 429 (62%) patients. At data cutoff, 230 (33%) patients had died. Age ≥ 60 years (hazard ratios 3.17–10.1 vs < 50 years), > 2 comorbidities (1.41 vs ≤ 2), acute myeloid leukemia (2.22 vs non-Hodgkin lymphoma) and active antineoplastic treatment with monoclonal antibodies (2·02) were associated with increased mortality; conventional chemotherapy showed borderline significance (1.50 vs no active therapy). Conversely, Ph-negative myeloproliferative neoplasms (0.33) and active treatment with hypomethylating agents (0.47) were associated with lower mortality. Overall, 574 (82%) patients received antiviral therapy. Mortality with severe/critical COVID-19 was higher with no therapy vs any antiviral combination therapy (2.20). Conclusions In this series of patients with hematologic malignancies and COVID-19, mortality was associated with higher age, more comorbidities, type of hematological malignancy and type of antineoplastic therapy. Further studies and long-term follow-up are required to validate these criteria for risk stratification.

Sign in / Sign up

Export Citation Format

Share Document